Piacibello W, Fubini L, Sanavio F, Brizzi M F, Severino A, Garetto L, Stacchini A, Pegoraro L, Aglietta M
Department of Biomedical Sciences and Human Oncology, Medical School of Torino, Italy.
Blood. 1995 Dec 1;86(11):4105-14.
A novel hematopoietic growth factor for primitive hematopoietic progenitor cells, the ligand for the flt3/flk2 receptor, (FL), has been recently purified and its gene has been cloned. In the present study, we investigated the effects of FL on the proliferation and differentiation of normal and leukemic myeloid progenitor cells. We demonstrate that FL is a potent stimulator of the in vitro growth of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), or G-CSF-dependent granulocyte-macrophage committed precursors from Lin- CD34+ bone marrow cells of normal donors. By contrast, FL does not affect the growth of erythroid-committed progenitors even in the presence of erythropoietin. The effect of FL on the proliferation and on the in vitro growth of clonogenic leukemic precursor cells was studied in 54 acute myeloid leukemia (AML) cases. Fresh leukemia blasts from 36 of 45 patients with AML significantly responded to FL without any relation to the French-American-British (FAB) subtype. FL stimulated the proliferation of leukemic blasts in a dose-dependent fashion. Synergistic activities were seen when FL was combined with G-CSF, GM-CSF, IL-3, or stem cell factor (SCF). FL as a single factor induced or increased significantly colony formation by clonogenic precursor cells from 21 of 24 patients with AML. In the presence of suboptimal and optimal concentrations of G-CSF, GM-CSF, IL3, SCF, or a combination of all factors, FL strongly enhanced the number of leukemic colonies (up to 18-fold). We also evaluated the induction of tyrosine phosphorylated protein on FL stimulation in fresh AML cells. We demonstrate that, on FL stimulation, a band of phosphorylated protein(s) of about 90 kD can be detected in FL-responsive, but not in FL-unresponsive cases. This study suggests that FL may be an important factor for the growth of myeloid leukemia cells, either as a direct stimulus or as a synergistic factor with other cytokines.
一种作用于原始造血祖细胞的新型造血生长因子,即fms样酪氨酸激酶3/胎儿肝脏激酶2受体(FLT3/FLK2)的配体,最近已被纯化,其基因也已克隆。在本研究中,我们调查了FL对正常和白血病髓系祖细胞增殖与分化的影响。我们证明,FL是来自正常供体的Lin-CD34+骨髓细胞中粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素-3(IL-3)或G-CSF依赖的粒细胞-巨噬细胞定向前体细胞体外生长的有效刺激剂。相比之下,即使在有促红细胞生成素存在的情况下,FL也不影响红系定向祖细胞的生长。我们在54例急性髓系白血病(AML)病例中研究了FL对克隆性白血病前体细胞增殖和体外生长的影响。45例AML患者中36例患者的新鲜白血病原始细胞对FL有显著反应,且与法美英(FAB)亚型无关。FL以剂量依赖方式刺激白血病原始细胞的增殖。当FL与G-CSF、GM-CSF、IL-3或干细胞因子(SCF)联合使用时,可观察到协同活性。FL作为单一因子可诱导或显著增加24例AML患者中21例患者克隆性前体细胞的集落形成。在G-CSF、GM-CSF、IL-3、SCF的次优和最佳浓度存在时,或所有因子联合存在时,FL强烈增加白血病集落数量(高达18倍)。我们还评估了新鲜AML细胞在FL刺激下酪氨酸磷酸化蛋白的诱导情况。我们证明,在FL刺激下,在对FL有反应的病例中可检测到一条约90kD的磷酸化蛋白条带,而在对FL无反应的病例中则检测不到。本研究表明,FL可能是髓系白血病细胞生长的重要因子,既可作为直接刺激因子,也可作为与其他细胞因子的协同因子。